ATE50266T1 - Biologisch wirksame peptide strukturell mit regionen von wachstumshormonen in verbindung stehend. - Google Patents

Biologisch wirksame peptide strukturell mit regionen von wachstumshormonen in verbindung stehend.

Info

Publication number: ATE50266T1
Authority: AT; Austria
Prior art keywords: sub; hgh; analogs; amino acid; acid residues
Prior art date: 1983-06-04

Application number

AT84106337T

Other languages

English (en)

Inventor

Theodore Jones

Christopher G Rudman

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-06-04

Filing date

1984-06-04

Publication date

1990-02-15

1984-06-04 Application filed by Amgen Inc filed Critical Amgen Inc

1990-02-15 Application granted granted Critical

1990-02-15 Publication of ATE50266T1 publication Critical patent/ATE50266T1/de

Links

108090000765 processed proteins & peptides Proteins 0.000 title abstract 5
102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
239000000122 growth hormone Substances 0.000 title abstract 2
102000018997 Growth Hormone Human genes 0.000 title 1
108010051696 Growth Hormone Proteins 0.000 title 1
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 4
125000000539 amino acid group Chemical group 0.000 abstract 3
239000012634 fragment Substances 0.000 abstract 3
102000004877 Insulin Human genes 0.000 abstract 2
108090001061 Insulin Proteins 0.000 abstract 2
229940125396 insulin Drugs 0.000 abstract 2
102000002265 Human Growth Hormone Human genes 0.000 abstract 1
108010000521 Human Growth Hormone Proteins 0.000 abstract 1
239000000854 Human Growth Hormone Substances 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
230000037430 deletion Effects 0.000 abstract 1
238000012217 deletion Methods 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000002218 hypoglycaemic effect Effects 0.000 abstract 1
241000894007 species Species 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/12—Growth hormone, growth factor other than t-cell or b-cell growth factor, and growth hormone releasing factor; related peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Endocrinology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Toxicology (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

AT84106337T 1983-06-04 1984-06-04 Biologisch wirksame peptide strukturell mit regionen von wachstumshormonen in verbindung stehend. ATE50266T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US06/501,024 US4699897A (en)	1983-06-04	1983-06-04	Biologically active peptides structurally related to regions within growth hormones
EP84106337A EP0137904B1 (de)	1983-06-04	1984-06-04	Biologisch wirksame Peptide strukturell mit Regionen von Wachstumshormonen in Verbindung stehend

Publications (1)

Publication Number	Publication Date
ATE50266T1 true ATE50266T1 (de)	1990-02-15

Family

ID=23991846

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT84106337T ATE50266T1 (de)	1983-06-04	1984-06-04	Biologisch wirksame peptide strukturell mit regionen von wachstumshormonen in verbindung stehend.

Country Status (8)

Country	Link
US (1)	US4699897A (de)
EP (1)	EP0137904B1 (de)
JP (1)	JPH07116229B2 (de)
AT (1)	ATE50266T1 (de)
CA (1)	CA1267995A (de)
DE (1)	DE3481306D1 (de)
IL (1)	IL72018A (de)
WO (1)	WO1984004915A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0238473A3 (de) *	1986-03-18	1989-06-07	Monsanto Company	Serinprotease-Hemmungsstoffe
US5104806A (en) *	1987-03-12	1992-04-14	Amgen, Inc.	Porcine growth hormone analogs encoding dna
US5244882A (en) *	1987-03-12	1993-09-14	Amgen, Inc.	Porcine growth hormone analogs, and compositions
GB8707398D0 (en) *	1987-03-27	1987-04-29	Coopers Animal Health	Biologically active molecules
GB8718937D0 (en) *	1987-08-11	1987-09-16	Coopers Animal Health	Biologically active molecules
JPH03503416A (ja) *	1988-03-25	1991-08-01	マリンクロットベタリナリィ，インコーポレイテッド	ペプチド
US5864008A (en) *	1988-03-25	1999-01-26	James; Stephen	Peptides derived from foot-and-mouth disease virus, pharmaceutical compositions, and methods for using the peptides
US5688666A (en) *	1988-10-28	1997-11-18	Genentech, Inc.	Growth hormone variants with altered binding properties
EP0397834B1 (de) *	1988-10-28	2000-02-02	Genentech, Inc.	Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten
US5534617A (en) *	1988-10-28	1996-07-09	Genentech, Inc.	Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US6780613B1 (en) *	1988-10-28	2004-08-24	Genentech, Inc.	Growth hormone variants
US5179080A (en) *	1989-08-31	1993-01-12	Clinical Homecare, Corp.	Formulations containing growth hormone and nutritional supplements, and methods of treating malnutrition in chronic lung disease
CA2095633C (en) *	1990-12-03	2003-02-04	Lisa J. Garrard	Enrichment method for variant proteins with altered binding properties
WO1993023067A1 (en) *	1992-05-08	1993-11-25	Thomas Jefferson University	Igf-1 analogs
SE9203496D0 (sv) *	1992-11-20	1992-11-20	Kabi Pharmacia Ab	New oligopeptides
US5952465A (en) *	1993-04-23	1999-09-14	Virginia Commonwealth University	Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site
AU6770794A (en) *	1993-04-23	1994-11-21	Herbert J. Evans	Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site
US5965698A (en) *	1993-04-23	1999-10-12	Virginia Commonwealth University	Polypeptides that include conformation-constraining groups which flank a protein--protein interaction site
US6258550B1 (en)	1993-04-23	2001-07-10	Virginia Commonwealth University	Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site
US5928896A (en) *	1993-04-23	1999-07-27	Virginia Commonwealth University	Polypeptides that include conformation-constraining groups which flank a protein--protein interaction site
US6084066A (en) *	1993-10-29	2000-07-04	Virginia Commonwealth University	Polypetides that include conformation-constraining groups which flank a protein-protein interaction site
US6184208B1 (en)	1994-06-29	2001-02-06	Immunotech Developments Inc.	Peptide, a method for its preparation and a pharmaceutical composition containing the peptide
RU2107691C1 (ru) *	1995-03-02	1998-03-27	Дейгин Владислав Исакович	Пептид и способ его получения
DK0851925T3 (da) *	1995-09-21	2005-11-28	Genentech Inc	Humane Væksthormonvarianter
US6159940A (en) *	1996-02-28	2000-12-12	Immunotech Developments Inc.	Method for modulating hemopoiesis
CA2534364A1 (en)	2003-08-07	2005-02-17	Alveolus Inc.	Therapeutic medical appliance, delivery and method of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2843525A (en) *	1953-01-23	1958-07-15	Allen & Hanburys Ltd	Insulin synthetic poly-amino acid complexes
US3326763A (en) *	1962-01-08	1967-06-20	Protein Foundation Inc	Reagent for increasing activity of insulin
US3698912A (en) *	1969-07-01	1972-10-17	Morton Norwich Products Inc	Process for making nutrient composition
US3868358A (en) *	1971-04-30	1975-02-25	Lilly Co Eli	Protamine-insulin product
US3912807A (en) *	1974-04-18	1975-10-14	American Home Prod	Treatment of diabetes using somatostatin and insulin
FR2296427A1 (fr) *	1974-12-31	1976-07-30	Choay Sa	Agent peptidique de regulation de la glycemie
US3941763A (en) *	1975-03-28	1976-03-02	American Home Products Corporation	PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
DE2658984C2 (de) *	1976-12-27	1983-08-18	Thera Gesellschaft für Patentverwertung mbH, 8036 Herrsching	Injizierbare Insulinpräparate
US4407948A (en) *	1977-09-23	1983-10-04	The Regents Of The University Of California	Purification of nucleotide sequences suitable for expression in bacteria
EP0053029A1 (de) *	1980-11-24	1982-06-02	Peninsula Laboratories Incorporated	Nicht-enkephalinartige Peptide, ihre Herstellung, sie enthaltende Zusammensetzungen und ihre medizinische und tierärztliche Verwendung
US4438032A (en) *	1981-01-30	1984-03-20	The Regents Of The University Of California	Unique T-lymphocyte line and products derived therefrom
US4558033A (en) *	1983-06-06	1985-12-10	Amgen	Potentiation of the effects of insulin by peptides

1983
- 1983-06-04 US US06/501,024 patent/US4699897A/en not_active Expired - Fee Related
1984
- 1984-06-01 CA CA000455648A patent/CA1267995A/en not_active Expired - Lifetime
- 1984-06-01 JP JP59502360A patent/JPH07116229B2/ja not_active Expired - Lifetime
- 1984-06-01 WO PCT/US1984/000834 patent/WO1984004915A1/en not_active Ceased
- 1984-06-04 AT AT84106337T patent/ATE50266T1/de not_active IP Right Cessation
- 1984-06-04 DE DE8484106337T patent/DE3481306D1/de not_active Expired - Fee Related
- 1984-06-04 IL IL72018A patent/IL72018A/xx not_active IP Right Cessation
- 1984-06-04 EP EP84106337A patent/EP0137904B1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
IL72018A0 (en)	1984-10-31
US4699897A (en)	1987-10-13
IL72018A (en)	1990-03-19
JPS60501504A (ja)	1985-09-12
EP0137904B1 (de)	1990-02-07
DE3481306D1 (de)	1990-03-15
JPH07116229B2 (ja)	1995-12-13
EP0137904A3 (en)	1987-01-07
CA1267995A (en)	1990-04-17
EP0137904A2 (de)	1985-04-24
WO1984004915A1 (en)	1984-12-20

Legal Events

Date	Code	Title	Description
1990-08-15	UEP	Publication of translation of european patent specification
2000-03-15	REN	Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE50266T1 (de)	1990-02-15	Biologisch wirksame peptide strukturell mit regionen von wachstumshormonen in verbindung stehend.
DE69630133T2 (de)	2004-06-09	Analoga des parathyroid-hormons
FI950169A0 (fi)	1995-01-13	PTH:n ja PTHRP:n analogit, niiden synteesi ja käyttö osteoporoosin hoitoon
DE69531889D1 (de)	2003-11-13	Biologisch aktive Fragmente des Glucagon ähnlichen, insulinotropen Peptides
ES2070322T3 (es)	1995-06-01	Polipeptidos biologicamente activos basados en las secuencias del factor de crecimiento de transformacion beta.
DE3853384D1 (de)	1995-04-27	Peptid.
RU97105374A (ru)	1999-04-20	Модифицированные белки
MX9703642A (es)	1998-11-29	Metodos para el tratamiento de esclerosis multiple utilizando analogos de peptido en la posicion 91 de la proteina basica de mielina humana.
DE3777845D1 (de)	1992-05-07	Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.
GR3031927T3 (en)	2000-03-31	Cysteine depleted il-6 muteins
MY103251A (en)	1993-05-29	Biologically active molecules
DK0523330T3 (da)	1996-04-15	Implanterbare sammensætninger indeholdende et biologisk aktivt protein, peptid eller polypeptid
FR2266516A1 (en)	1975-10-31	Somatostatin peptide analogues having prolonged activity - inhibit secretion of pituitary growth hormone and glucagon and are used to treat diabetes
MY103759A (en)	1993-09-30	Biologically active molecules
TW360661B (en)	1999-06-11	Superactive GRF analogs
YU64192A (sh)	1994-06-10	Analozi insulina
Oelofsen	1975	The chemistry of the adrenocorticotropins and the melanotropins
HUT54388A (en)	1991-02-28	Process for producing new analogues of stimulator hormone for growth hormone secretion (grf)
Potts Jr et al.	1972	Comparative biochemistry of parathyroid hormone and calcitonin
KR890002395A (ko)	1989-04-10	인터루킨-2 활성을 갖는 폴리펩타이드
IT1157194B (it)	1987-02-11	Procedimento per la produzione di nuovi ciclopeptidi e prodotti cosi' ottenuti